Verified Nov 2026
Batteries & E-Mobility
·

Boston, Massachusetts
·
Since 1989
Vertex Pharmaceuticals is a Boston-based biopharmaceutical company founded in 1989 with 5,000–10,000 employees and revenue exceeding $10 billion. The company discovers, develops, and commercializes small-molecule drugs and gene-editing therapies for serious diseases including cystic fibrosis, sickle cell disease, and beta thalassemia, serving patients and healthcare providers across the Americas, Europe, Asia, and the Middle East.
Vertex Pharmaceuticals at a glance
Revenue
$10B+
Est. band
Employees
5,000-10,000
Founded
1989
Headquarters
Boston, Massachusetts
Import activity
16
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
16
Named foreign suppliers
12
Top origins
United Kingdom · Belgium · Netherlands · Germany

Shared foreign counterparties do not establish that these companies buy from Vertex Pharmaceuticals.
What this tells a buyer
The company received pharmaceutical equipment shipments from multiple European suppliers in Switzerland, Germany, the United Kingdom, Italy, Belgium, and the Netherlands, indicating a distributed supply chain for manufacturing and development operations.
Vertex markets approved therapies including TRIKAFTA for cystic fibrosis, CASGEVY as the first FDA-approved CRISPR-based gene therapy for sickle cell disease and beta thalassemia, and JOURNAVX for acute pain management.
In September 2026, Vertex completed the acquisition of Crinetics Pharmaceuticals and expanded its executive leadership team as part of its strategic growth.
Source: US customs bill-of-lading records and public filings · Last verified Nov 16, 2026
STABILITY SIGNALS
Established & active
37 years in operation (founded 1989).
16 US import shipments on record.
Overview
Vertex Pharmaceuticals is a Boston-based biopharmaceutical company founded in 1989 with 5,000–10,000 employees and revenue exceeding $10 billion. The company discovers, develops, and commercializes small-molecule drugs and gene-editing therapies for serious diseases including cystic fibrosis, sickle cell disease, and beta thalassemia, serving patients and healthcare providers across the Americas, Europe, Asia, and the Middle East.
At a glance
Attribute | Detail |
|---|---|
Founded | 1989 |
Headquarters | Boston, Massachusetts |
Employees | 5,000-10,000 |
Revenue | $10B+ (estimated) |
Primary capability | Batteries & E-Mobility |
What Vertex Pharmaceuticals makes
Vertex markets approved therapies including TRIKAFTA for cystic fibrosis, CASGEVY as the first FDA-approved CRISPR-based gene therapy for sickle cell disease and beta thalassemia, and JOURNAVX for acute pain management.
Trade and customs footprint
The company received pharmaceutical equipment shipments from multiple European suppliers in Switzerland, Germany, the United Kingdom, Italy, Belgium, and the Netherlands, indicating a distributed supply chain for manufacturing and development operations. US customs bill-of-lading records list 16 inbound shipments across 12 foreign suppliers, with top origins including United Kingdom · Belgium · Netherlands · Germany.
Latest developments
2026-11-16 — Vertex at UBS Global Biopharma Conference 2026: renal push gains pace By Investing.com (investing.com)
2026-11-02 — Vertex Reports Third Quarter 2026 Financial Results | Vertex Pharmaceuticals Newsroom (gcs-web.com)
2026-09-01 — Vertex Pharmaceuticals | Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team (vrtx.com)
2026-04-07 — Halozyme and Vertex (VRTX) announce Hypercon™ license deal | Grafa (grafa.com)
2025-10-14 — Vertex dives into covalent biologics | Nature Biotechnology (nature.com)
2025-09-02 — Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases - Enlaza Therapeutics (enlazatx.com)
Company details
In September 2026, Vertex completed the acquisition of Crinetics Pharmaceuticals and expanded its executive leadership team as part of its strategic growth. Vertex Pharmaceuticals was founded in 1989, has an estimated 5,000-10,000 employees, and is headquartered in Boston, Massachusetts. On the LightSource stability read it is rated "Established & active": 37 years in operation (founded 1989). 16 US import shipments on record.
Frequently asked questions
What does Vertex Pharmaceuticals make?
Vertex Pharmaceuticals is a Boston-based biopharmaceutical company founded in 1989 with 5,000–10,000 employees and revenue exceeding $10 billion. The company discovers, develops, and commercializes small-molecule drugs and gene-editing therapies for serious diseases including cystic fibrosis, sickle cell disease, and beta thalassemia, serving patients and healthcare providers across the Americas, Europe, Asia, and the Middle East.
Where is Vertex Pharmaceuticals headquartered?
Vertex Pharmaceuticals is headquartered in Boston, Massachusetts (50 Northern Avenue, Boston, Massachusetts, 02210).
When was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989.
How big is Vertex Pharmaceuticals?
Vertex Pharmaceuticals has an estimated 5,000-10,000 employees, with revenue in the $10B+ range (estimated).
Does Vertex Pharmaceuticals import from overseas suppliers?
US customs bill-of-lading records show 16 inbound shipments for Vertex Pharmaceuticals, with top origins including United Kingdom · Belgium · Netherlands · Germany.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
